by Natthaphon Sangpolsit

    

BANGKOK (NNT) - The government plans to procure a long-acting antibody drug for people with conditions that prevent them from getting vaccinated against COVID-19.

 

According to Government Spokesperson Thanakorn Wangboonkongchana, the Center for COVID-19 Situation Administration (CCSA) has approved a plan to procure Evusheld, a long-acting monoclonal antibody designed to prevent COVID transmissions, specifically for individuals with poor immune systems who cannot get vaccinated.

 

Keep up to date with all things Thailand - Join our daily ASEAN NOW Thailand Newsletter - Click to subscribe

 

Evusheld was developed by AstraZeneca using a combination of two long-acting antibodies, tixagevimab and cilgavimab, which work by binding to the spike protein on the outside of the SARS-CoV-2 virus, preventing it from attaching to and entering human cells. It is administered in two injections and provides protection for at least six months.

 

The government is currently exploring options for obtaining Evusheld, including renegotiating with AstraZeneca to replace some vaccine doses with Evusheld in order to reduce additional payments.

 

Discover Cigna’s range of health insurance solutions created for expats and local nationals living in Thailand - click to view

 

-- © Copyright NNT 2022-04-11

 

- Aetna offers a range of visa-compliant plans that meet the minimum requirement of medical treatment, including COVID-19, up to THB 3m. For more information on all expat health insurance plans click here.

 

- Follow ASEAN NOW on LINE for breaking COVID-19 updates

 

Good Idea, Get Paxlovid as well and distribute it to masses. Time to ooen economy with caution, care and compassion.

Never seems to be any news about Siam Bioscience. How many doses is it producing? Where are they going? I mean, don't they want kudos...if any are deserved?